



OPEN ACCESS

EDITED AND REVIEWED BY
Melissa A. St. Hilaire,
Merrimack College, United States

*CORRESPONDENCE
Sandra P. Smieszek
✉ sandra.smieszek@vandapharma.com

RECEIVED 27 November 2023
ACCEPTED 18 December 2023
PUBLISHED 08 January 2024

CITATION
Smieszek SP, Kaden AR, Johnson CE,
Brzezynski JL, Xiao C, Polymeropoulos CM,
Birznieks G, Emsellem HA and
Polymeropoulos MH (2024) Corrigendum:
Case report: A patient with Delayed
Sleep-Wake Phase Disorder and Optic Nerve
Hypoplasia treated with tasimelteon: a case
study. *Front. Neurosci.* 17:1344915.
doi: 10.3389/fnins.2023.1344915

COPYRIGHT
© 2024 Smieszek, Kaden, Johnson,
Brzezynski, Xiao, Polymeropoulos, Birznieks,
Emsellem and Polymeropoulos. This is an
open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](#). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic practice.
No use, distribution or reproduction is
permitted which does not comply with these
terms.

Corrigendum: Case report: A patient with Delayed Sleep-Wake Phase Disorder and Optic Nerve Hypoplasia treated with tasimelteon: a case study

Sandra P. Smieszek^{1*}, Alyssa R. Kaden¹, Caroline E. Johnson¹,
Jennifer L. Brzezynski¹, Changfu Xiao¹,
Christos M. Polymeropoulos¹, Gunther Birznieks¹,
Helene A. Emsellem^{2,3} and Mihael H. Polymeropoulos¹

¹Vanda Pharmaceuticals Inc., Washington, DC, United States, ²The Center for Sleep & Wake Disorders, Chevy Chase, MD, United States, ³Department of Neurology, George Washington University, Washington, DC, United States

KEYWORDS

biological rhythms, circadian rhythm disorders, clinical trials research, sleep/wake mechanisms, Delayed Sleep-Wake Phase Disorder, delayed sleep, night owl, Optic Nerve Hypoplasia

A corrigendum on

Case report: A patient with Delayed Sleep-Wake Phase Disorder and Optic Nerve Hypoplasia treated with tasimelteon: a case study

by Smieszek, S. P., Kaden, A. R., Johnson, C. E., Brzezynski, J. L., Xiao, C., Polymeropoulos, C. M., Birznieks, G., Emsellem, H. A., and Polymeropoulos, M. H. (2023). *Front. Neurosci.* 17:1287514. doi: 10.3389/fnins.2023.1287514

In the published article, there was an error. (There was an omission).

A correction has been made to **Discussion**, Paragraph 4. This sentence previously stated:

“This participant is not a carrier of the variable number of tandem repeat (VNTR) *PER3*^{4/4} genotype, associated with delayed sleep patterns, nor the *CRY1* splicing variant (Patke et al., 2017). No other predicted loss-of-function mutations within circadian genes were identified.”

The corrected sentence appears below:

“This participant is not a carrier of the variable number of tandem repeat (VNTR) *PER3*^{4/4} genotype, associated with delayed sleep patterns, nor the *CRY1* splicing variant (Patke et al., 2017). This patient has been determined to carry two 5' UTR region variants in the Atonal BHLH Transcription Factor 7 (*ATOH7*) gene known to be associated with ONH, rs61854782 and rs7916697. *ATOH7* is expressed in retinal progenitor cells and has a crucial role in retinal ganglion cell development. No other predicted loss-of-function mutations within circadian genes were identified.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

- Patke, A., Murphy, P., Onat, O., Krieger, A., Özçelik, T., Campbell, S., et al. (2017). Mutation of the human circadian clock gene *CRY1* in familial delayed sleep phase disorder. *Cell* 169, 203–215.e1. doi: 10.1016/j.cell.2017.03.027